Atrogi
@atrogi.com
We are a clinical-stage biotech company pioneering first-in-class treatments to revolutionize metabolic health. Our mission is to redefine the management of diabetes, obesity, and other metabolic diseases, by harnessing the potential of small molecules with distinct and novel signaling profiles.
Atrogi's Company Logos
Atrogi's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#212A40
Ebony Clay
33, 42, 64
223, 32, 19
48, 34, 0, 75
#295587
St Tropaz
41, 85, 135
212, 53, 35
70, 37, 0, 47
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
About Atrogi
Atrogi is a brand founded in 2013 by Professor Tore Bengtsson, supported by private investors. The brand focuses on improving people's lives through groundbreaking research and scientific expertise. With extensive experience in research and development, Atrogi has developed a revolutionary solution for the treatment of type 2 diabetes, aiming to minimize side effects. The brand's strength lies in its competitive intellectual property strategy and robust patent portfolio.
Atrogi's team consists of leading experts with a deep understanding of clinical studies and business development. Their goal is to create value by bringing their innovative treatment for type 2 diabetes to the global market. With a strong focus on marketable results, Atrogi combines scientific research, clinical development, and business acumen to ensure success.
The brand's team includes professionals such as CEO Alexandra Ekman Ryding, professor Tore Bengtsson, head of chemistry and IP Benjamin Pelcman, head of biology Nodi Dehvari, and other specialized research scientists and technicians. With their combined expertise, Atrogi is well-positioned to transform the treatment of type 2 diabetes and positively impact the lives of millions of people worldwide.
